BRAINTEASER project aims to support patients with amyotrophic lateral sclerosis and multiple sclerosis and their clinicians. “Amyotrophic Lateral Sclerosis” campaign wants to bring attention to this condition and analyse the variables that might affect its progression. In “The use of biotelemetry to explore disease progression markers in amyotrophic lateral sclerosis” M. Kelly et al. report the results of an exploratory, non-controlled, nondrug study that aimed to objectively monitor ALS patients at home, to explore novel disease progression markers.
[Get to Know more about Amyotrophic Lateral Sclerosis] The use of biotelemetry to explore disease
OUR NEWSLETTER
Latest posts
An Interview with Nicola Ferro: Discovering The iDPP@CLEF Challenge 2022
BRAINTEASER is excited to take part in the iDPP@CLEF Challenge 2022 happening on 5-8 September, We...
BRAINTEASER presents its first open evaluation challenge at ECIR
ECIR is the premier European conference on Information Retrieval and Information Access (CORE Rank...
iDPP@CLEF 2022: Intelligent Disease Progression Prediction at CLEF
Amyotrophic Lateral Sclerosis (ALS) is a chronic disease, characterized by progressive or...